Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lenalidomide

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

- PMLiVE

Interview: Trevor Smith, Takeda

Takeda’s head of commercial operations for Europe and Canada talks about the integration of Nycomed and European market access

- PMLiVE

Takeda acquires US-based drug discovery company Envoy

Japanese pharma firm gains target identification technology and preclinical CNS assets

- PMLiVE

Acquisitions soften Actos blow in Takeda’s first-half results

URL Pharma and Nycomed purchases help sales increase 12 per cent to 787bn yen

Pharma must ’embrace the new reality’ and meet payers’ needs

This means capturing better health economic data during product development, says Takeda's Trevor Smith

- PMLiVE

Takeda pays $60m for vaccine company LigoCyte

Gains first-in-class norovirus candidate and new vaccine platform

- PMLiVE

Takeda completes new manufacturing facility in Russia

Expands Japanese firm’s presence in key emerging market

- PMLiVE

Takeda’s Revestive becomes first approved drug in Europe for short bowel syndrome

Can reduce dependency on intravenous feeding

- PMLiVE

COPD needs to learn risk reductions lessons from heart disease

Takeda-backed report says HCPs working in COPD need to learn from progress made by their colleagues in cardiovascular medicine

Amgen-Takeda’s ganitumab fails in pancreatic cancer study

Interim analysis shows no improvement in overall survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links